Developing novel therapeutics for Alzheimer's and other neurodegenerative diseases
info@cogrx.com

Cognition Therapeutics Announces Issuance of Broad Composition of Matter Patent for CT1812, a First-in-Class Alzheimer’s Disease Clinical Candidate

Pittsburgh, Oct. 24, 2017 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a composition of matter patent for CT1812, Cognition’s first-in-class, orally available Alzheimer’s disease drug candidate.

US Patent No. 9,796,672, “Isoindoline compositions and methods for treating neurodegenerative disease,” arises from the inventive work of Cognition’s scientific team led by Cognition co-founders Susan Catalano, Ph.D. and Gilbert Rishton, Ph.D., as well as colleague Gary Look, Ph.D. The small molecule covered by this patent was designed to inhibit the binding of beta amyloid (Aß) oligomers to neuronal receptors and facilitate clearance of Aß oligomers into the cerebrospinal fluid, with the goal of mitigating the toxic effects of Aß oligomers that lead to the synapse loss characteristic of Alzheimer’s disease and other neurodegenerative conditions. The newly issued patent provides Cognition with protection for CT1812 in the United States through 2034. Additional time may be secured through patent term extension based upon regulatory review. Cognition also has filed corresponding patent applications to seek similar patent protection in key markets throughout the world.

“This patent is the result of the focused efforts of researchers dedicated to developing novel medicines against Alzheimer’s disease,” commented Cognition President & CEO Kenneth I. Moch, “CT1812 has a unique mechanism of action that blocks the binding of Aß oligomers to the synapses on neurons, a process that has been directly implicated in the cognitive decline associated with Alzheimer’s disease. Looking to 2018, we will be building on the results of our recently completed CT1812 Phase 1b/2a study by undertaking additional mechanism of action clinical studies and a larger Phase 2 study of CT1812 in patients with Alzheimer’s disease.”

About CT1812
Cognition’s lead product candidate, CT1812, has completed a Phase 1b/2a clinical study (COG0102) in patients with mild-to-moderate Alzheimer’s disease and has been granted Fast Track designation by the US FDA. This highly brain penetrant compound targets the sigma-2 receptor complex on neuronal synapses, displacing toxic beta amyloid (Aß) oligomers from their binding sites on brain cells and clearing them into the cerebrospinal fluid. CT1812 has been shown in multiple Alzheimer’s disease models to stop memory loss. Results from Study COG0102 will be announced in a late-breaker oral presentation at the CTAD (Clinical Trials on Alzheimer’s Disease) meeting in Boston taking place November 2-4, 2017.

About Cognition Therapeutics, Inc.
Cognition Therapeutics is a privately held biopharmaceutical company developing a pipeline of disease modifying small molecule drug candidates to treat neurocognitive disorders. Cognition’s lead candidate, CT1812, is a proprietary first-in-class, orally available small molecule in development for the treatment of mild-to-moderate Alzheimer’s disease. CT1812 and Cognition’s other pipeline candidates were identified using the company’s disease-relevant screening and novel chemistry platforms. Additional information about Cognition and its product candidates may be found online at http://www.cogrx.com.

Forward-Looking Statements
This press release contains “forward-looking statements” concerning the development and commercialization of Cognition’s products, the potential benefits and attributes of such products, and Cognition’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Cognition undertakes no obligation to update any forward-looking statements for any reason.